Warfarin necrosis

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Fibroblast, EGFR, Warfarin necrosis, Risk, Communication, IL-6, Form, Diabetic foot ulcer, Conditional sentence, Patient, Research, Mouse, Gamma ray, Trial of the century, HDF, Hyperglycemia, Acceleration, Wound healing, Cytokine, Therapy, Cellular senescence, Interleukin, VEGF, Pharmaceutical industry

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

Global IgG Mediated Autoimmune Diseases Biologic Drugs Research Report 2024: A Highly Competitive Market with Pharmaceutical and Biotechnology Firms Competing for the $197.75 Billion Market Share - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Health, Psoriasis, Warfarin necrosis, Rheumatoid arthritis, Prevalence, Growth, Porter's five forces analysis, Lupus, Incidence, Inflammation, SWOT, Multiple sclerosis, Humanized antibody, ILS, Autoimmune disease, Immune system, Cytokine, Inflammatory bowel disease, USD, Immunoglobulin G, Interleukin, Ageing, Vaccine

The Global IgG Mediated Autoimmune Diseases Biologic Drugs market showcased growth at a CAGR of 7.25% during 2019-2022.

Key Points: 
  • The Global IgG Mediated Autoimmune Diseases Biologic Drugs market showcased growth at a CAGR of 7.25% during 2019-2022.
  • The increasing incidence and prevalence of IgG mediated autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are major drivers for the growth of biologic drugs.
  • The global market for IgG mediated autoimmune diseases biologic drugs is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.
  • The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources)
    The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications).

Global Infliximab Drug Market to 2031 Set to Expand with Rising Rheumatoid Arthritis Cases - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Pharmaceutical, Health, Other Health, Infliximab, Lupus, TNF, Prevalence, Eye, Skin, Ankylosing spondylitis, SLE, Inflammation, Multiple sclerosis, Ulcerative colitis, Psoriasis, Crohn's disease, Patient, Hidradenitis suppurativa, Uveitis, Nonsteroidal anti-inflammatory drug, Immune system, Warfarin necrosis, Growth, Pyoderma gangrenosum, Rheumatoid arthritis, Vaccine

The "Global Infliximab Drug Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infliximab Drug Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the global infliximab drug market is driven by the rising number of rheumatoid arthritis cases.
  • The prevalence of rheumatoid arthritis disease is likely to grow at a CAGR of 1.0% in the forecast period of 2023-2031.
  • Infliximab is a monoclonal antibody that is used to treat autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Retrieved on: 
Tuesday, December 6, 2022
Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science, Society, RA, Mouse, TNF, Genta (company), Rheumatoid arthritis, MD, Infection, CAIA, Chronic pain, Patient, Annual report, British Society for Immunology, Ankylosing Spondylitis Quality of Life, FDA, Degenerative disease, COVID-19, CB2, Inflammation, Trial of the century, Ageing, Safety, Arthritis, Congress, Autoimmunity, BSI, Warfarin necrosis, Anxiety, Seizure, CNS, Pharmaceutical industry, Dietary supplement, CBD, Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Other Science, Science

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
  • In-life results showed percent change of inflammation relative to control was reduced by 37% with MYMD-1 while reduction was 29% with etanercept at 10 mg/kg/day.
  • Its ease of oral dosing is a significant differentiator compared to currently available TNF- inhibitors, all of which require delivery by injection or infusion.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases.

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

Retrieved on: 
Monday, November 14, 2022
Trial of the century, Communication, Survival, Neck, Lymph, National Cancer Institute, Type 1, CT scan, Cancer, Mayo Clinic, Disease, Radiation, PDS, Toxicity, Immunotherapy, Treatment, Vaccine, Cervical cancer, Blood, Partnership, PET, University, Neoplasm, Research, Nature, Society, MD Anderson Cancer Center, Biotechnology, COVID-19, Merck & Co., Vulvar cancer, Warfarin necrosis, NCI, Merck, MRI, Human, CD8, Sharp, Nominal interest rate, Clinical professor, Therapy, FIGO, CRT, CPI, Gamma ray, III, Risk, Infection, Merck Sharp & Dohme Federal Credit Union, PDSB, Positron emission tomography, CR, Head, SITC, Pharmaceutical industry, Medical imaging, Patient

FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022). These data expand upon results detailed in the abstract submitted to SITC 2022 that was released to the public on November 7.

Key Points: 
  • This includes 78% (7/9) of treated patients with advanced cervical cancer (FIGO stage III or IV).
  • 100% (9/9) of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.
  • We look forward to the continued advancement of the IMMUNOCERV Phase 2 clinical trial and the opportunity to report updated data during 2023.
  • A third Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer is being led by The University of Texas MD Anderson Cancer Center.

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Retrieved on: 
Thursday, November 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, FDA, Warfarin necrosis, Anxiety, Chronic pain, British Society for Immunology, CB2, CAIA, Rheumatoid arthritis, Thyroiditis, Sarcopenia, Patient, Ageing, Pharmacology, RA, Human, Inflammation, CNS, BSI, Safety, MS, Immune system, Degenerative disease, Society, Arthritis, Frailty, Annual report, Congress, Central nervous system, Multiple sclerosis, COVID-19, Seizure, TNF, Genta (company), Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
  • We believe strongly in the potential of MYMD-1 as a next-generation TNF- inhibitor.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases.
  • Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements.

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Retrieved on: 
Monday, November 14, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, FDA, Warfarin necrosis, Anxiety, Chronic pain, CB2, Rheumatoid arthritis, Thyroiditis, Sarcopenia, Patient, Ageing, RA, Inflammation, CNS, Safety, MS, Degenerative disease, Immune system, Frailty, Drug development, Central nervous system, Multiple sclerosis, COVID-19, Seizure, Infection, TNF, Pharmaceutical industry, CBD

MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based autoimmune diseases are treated.

Key Points: 
  • MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based autoimmune diseases are treated.
  • Its ease of oral dosing is a significant differentiator compared to currently available TNF- inhibitors, all of which require delivery by injection or infusion.
  • In addition, it has not been shown to cause serious side effects common with traditional immunosuppressive therapies that treat inflammation.
  • MYMD-1 is currently being evaluated in Phase 2 studies for sarcopenia/frailty, a result of the aging process, with data expected in 4Q 2022.

Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, GPC3, Private Securities Litigation Reform Act, Forward-looking statement, Congress, Baylor University, Liver cancer, U.S. Securities and Exchange Commission, International Society, SIOP, Colorectal cancer, Warfarin necrosis, Nasdaq, MCRPC, International Society of Paediatric Oncology, Hepatocellular carcinoma, Annual report, Center, Sale, HER2, Cell, COVID-19, Cancer, HCC, Gene, Breast, Baylor College of Medicine, Lung, D, Form 10-K, Research, Patient, Security (finance), IL-6, Center for Cell and Gene Therapy, FDA, Income, Pharmaceutical industry, Vaccine, Medicine

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update.

Key Points: 
  • HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update.
  • In May 2022, the FDA announced a shortage of fludarabine in the U.S. that is affecting the companys clinical trial sites.
  • At the end of the third quarter of 2022, Bellicum had 11 full time equivalent R&D employees, compared to 5 at the end of the third quarter of 2021.
  • Shares Outstanding: As of November 4, 2022, Bellicum had 8,613,527 shares of common stock and 452,000 shares of preferred stock outstanding.

Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38

Retrieved on: 
Monday, October 10, 2022
VEGA, United European Gastroenterology, Mayo, Johnson & Johnson, Patient, AES, Janssen Pharmaceuticals, Gastroenterology, SPRING, HOUSE, TNF, UC, Congress, Safety, Icahn School of Medicine at Mount Sinai, Randomized controlled trial, Maintenance, Ulcerative colitis, Warfarin necrosis, UEG, Mount Sinai, Pharmaceutical industry, Medicine

SPRING HOUSE, Pa., Oct. 10, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab alone (20.8 percent).1,2 Patients had comparable rates of adverse events (AEs) across the treatment groups.1 Guselkumab alone, or the combination of guselkumab and golimumab are under clinical investigation and not approved for the treatment of adults with UC in the U.S.

Key Points: 
  • Endoscopic remissionh and histologic remissioni were higher in patients who received combination therapy followed by treatment with guselkumab compared to patients who received golimumab alone.
  • Modified Mayo score consists of three of the four components of the full Mayo score: stool frequency, rectal bleeding, and endoscopic score.
  • Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA.
  • Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

Ulcerative Colitis Market Forecasts, Epidemiology & Pipeline Analysis 2022-2027: Focus on 8 Major Markets - United States, France, Germany, Italy, Spain, United Kingdom, China, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Biotechnology, Pharmaceutical, Health, AbbVie, NDA, Inflammatory bowel disease, UC, Safety, Mirikizumab, Research, Warfarin necrosis, Therapy, Filgotinib, Awareness, US Foods, Ulcerative colitis, Man, Galápagos Islands, Allergan, Novartis, USFDA, Disease management, Pfizer, Investment, Disease, David Berry (inventor), Takeda Pharmaceutical Company, Prevalence, FDA, CAGR, Johnson & Johnson, Knowledge, Clinical trial, Woman, Acquisition, Growth, Industry, Patient, Pharmaceutical industry, Dietary supplement, Fine chemical, Health insurance, Adalimumab, Upadacitinib, Proctitis, Epidemiology, Ulcer, Phase

The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries.

Key Points: 
  • The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries.
  • The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.
  • The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market.
  • Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis.